Inven2 - Oslo University & Hospital Technology Transfer Office

Inven2 was formed in 2010 through the merger of Medinnova (Rikshospitalet's technology transfer office), Birkeland Innovasjon and the University of Oslo's own TTO. It is jointly owned by the University of Oslo and Oslo University Hospital, and also administers commercialisation of inventions across the wider South-Eastern Norway Regional Health Authority; an independent review by patent-law firm Dehns describes it as the largest technology transfer office in the Nordic region.
In 2024, Inven2's portfolio of roughly 50 companies (2 newly established that year) raised NOK 670 million for development, up from NOK 333 million in 2023, while NOK 24 million was returned to research and innovation through licence income and share sales in 2024 (NOK 36 million in 2023). At the end of 2023 Inven2 had 125 ongoing commercialisation projects.
The portfolio's reported combined value swung from roughly NOK 11 billion in 2023 to roughly NOK 5 billion in 2024 in Inven2's own summaries, a large year-on-year shift that is not explained in available sources and should be treated cautiously. Only 2 new companies were formed in 2024 despite the higher capital raised, suggesting the model is currently oriented toward scaling existing portfolio companies rather than high-volume new spin-off creation.

Read the full analysis: https://annual.inven2.com/2024/